Mercks Fosamax next legal battleground?
In the wake of the recent $15 million Vioxx verdict, plaintiffs’ attorneys are already setting their sights on Merck’s Fosamax. That according to a Wall Street Journal report Wednesday, which said that Merck’s top-selling osteoporosis drug Fosamax is the second drug made by the embattled company to come into the crosshairs of the medical tort bar. A lawsuit was filed this week in Fort Myers, Fla., the report said, with the plaintiffs seeking class-action status.
